Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Prostaglandins, Leukotrienes and Essential Fatty Acids

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1054/PLEF.1999.0064PMID 10477035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.

  1998cited by this paper
• Antecedent Aspirin Therapy Inhibits Baseline Platelet Activity in Patients Presenting with Acute Myocardial Infarction

  1998cited by this paper
• Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction.

  1998cited by this paper
• Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.

  1998cited by this paper
• Serial changes of the plasma prostanoids during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor.

  1997cited by this paper
• Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects.

  1997cited by this paper
• Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease.

  1997cited by this paper
• Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors.

  1996cited by this paper
• Arachidonic Acid Metabolites in Acute Myocardial Infarction

  1996cited by this paper
• Time course of platelet alpha granule release in acute myocardial infarction treated with streptokinase.

  1996cited by this paper
• Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)

  1995cited by this paper
• Implications of the prognostic importance of exercise-induced thromboxane formation in survivors of an acute myocardial infarction.

  1995cited by this paper
• New concepts regarding events that lead to myocardial infarction

  1995cited by this paper
• PGI2 analogue, sodium beraprost, suppresses superoxide generation in human neutrophils by inhibiting p47phox phosphorylation.

  1995cited by this paper
• Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products.

  1995cited by this paper
• Randomized Trial of Ridogrel, a Combined Thromboxane A2 Synthase Inhibitor and Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist, Versus Aspirin as Adjunct to Thrombolysis in Patients With Acute Myocardial Infarction: The Ridogrel Versus Aspirin Patency Trial (RAPT)

  1994cited by this paper
• Beraprost sodium protects occlusion/reperfusion injury in the dog by inhibition of neutrophil migration.

  1994cited by this paper
• Effects of a Thromboxane Synthetase Inhibitor, Y‐20811, on Infarct Size, Neutrophil Accumulation, and Arrhythmias After Coronary Artery Occlusion and Reperfusion in Dogs

  1993cited by this paper
• Increased production of thromboxane A2 by coronary arteries after thrombolysis.

  1993cited by this paper
• Antithrombotic therapy in the secondary prevention of myocardial infarction.

  1993cited by this paper
• A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart.

  1993cited by this paper
• Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury.

  1993cited by this paper
• Possible role of defibrotide in endothelial cell protection.

  1993cited by this paper
• Pharmacokinetics of Tissue‐Type Plasminogen Activator During Acute Myocardial Infarction in Men: Effect of a Prostacyclin Analogue

  1992cited by this paper
• Prostacyclin production in myocardial infarction in the acute phase and during follow‐up

  1991cited by this paper
• Effect of cicletanine on reperfusion-induced arrhythmias and its relation to 6-keto-PGF1 alpha and thromboxane B2 release.

  1991cited by this paper
• Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris.

  1990cited by this paper
• Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

  1990cited by this paper
• Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers.

  1990cited by this paper
• Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction.

  1988cited by this paper
• Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.

  1988cited by this paper
• Platelet prostacyclin binding in coronary artery disease.

  1986cited by this paper
• Platelet activation in unstable coronary disease.

  1986cited by this paper
• Platelet hyperactivity in acute myocardial infarction in man--effects of prostacyclin.

  1986cited by this paper

• Cardiac-generated prostanoids mediate cardiac myocyte apoptosis after myocardial ischaemia.

  2012cites this paper
• Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention

  2011cites this paper
• Angiogenic Function of Prostacyclin Biosynthesis in Human Endothelial Progenitor Cells

  2008cites this paper
• Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs.

  2007cites this paper
• BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.

  2007cites this paper
• Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.

  2004cites this paper
• Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?

  2003cites this paper
• The role of endothelial cell-derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue.

  2002cites this paper
• Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes? ☆ ☆☆ ★ ★★

  2002cites this paper
• In the presence of L‐NAME SERCA blockade induces endothelium‐dependent contraction of mouse aorta through activation of smooth muscle prostaglandin H2/thromboxane A2 receptors

  2002cites this paper
• Cyclooxygenase Inhibition as a Strategy to Ameliorate Brain Injury

  2002cites this paper
• Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure

  2001cites this paper